Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells

• Published in: Journal of cellular biochemistry Vol. 112; no. 1; pp. 10 - 29
• Main Authors: Oliveras-Ferraros, Cristina, Vazquez-Martin, Alejandro, Cufí, Sílvia, Queralt, Bernardo, Báez, Luciana, Guardeño, Raquel, Hernández-Yagüe, Xavier, Martin-Castillo, Begoña, Brunet, Joan, Menendez, Javier A.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.01.2011
• Subjects: Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal, Humanized; Antineoplastic Agents - pharmacology; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - metabolism; CD24 Antigen - metabolism; Cell Line, Tumor; Cetuximab; Down-Regulation; EGFR ligands; EMT; Epithelial-Mesenchymal Transition - drug effects; Female; Gene Regulatory Networks; Humans; Hyaluronan Receptors - metabolism; KRAS; Neoplasms, Squamous Cell - drug therapy; Neoplasms, Squamous Cell - metabolism; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins - metabolism; Proto-Oncogene Proteins p21(ras); ras Proteins - genetics; ras Proteins - metabolism; Receptor, Epidermal Growth Factor - metabolism; stem cells; Vulvar Neoplasms - drug therapy; Vulvar Neoplasms - metabolism
• ISSN: 0730-2312; 1097-4644
• DOI: 10.1002/jcb.22952

Beyond a well‐recognized effect of KRAS mutations in determining de novo inefficacy of cetuximab (CTX) in metastatic colorectal cancer, we urgently need a biomarker signature for predicting CTX efficacy in KRAS wild‐type (WT) tumors. CTX‐adapted EGFR gene‐amplified KRAS WT tumor cell populations were induced by stepwise‐chronic exposure of A431 epidermoid cancer cells to CTX. Genome‐wide analyses of 44K Agilent's whole human arrays were bioinformatically evaluated by Gene Set Enrichment Analysis (GSEA)‐based screening of the KEGG pathway database. Molecular functioning of CTX was found to depend on: (i) The occurrence of a positive feedback loop on Epidermal Growth Factor Receptor (EGFR) activation driven by genes coding for EGFR ligands (e.g., amphiregulin); (ii) the lack of a negative feedback on mitogen‐activated protein kinase (MAPK) activation regulated by dual‐specificity phosphatases (e.g., DUSP6) and; (iii) the transcriptional status of gene pathways controlling the epithelial‐to‐mesenchymal transition (EMT) and its reversal (MET) program (actin cytoskeleton and cell–cell communication—e.g., keratins—focal adhesion signaling—e.g., integrins—and EMT‐inducing cytokines – e.g., transforming growth factor‐β). Quantitative real‐time PCR, high‐content immunostaining, and flow‐cytometry analyses confirmed that CTX efficacy depends on its ability to promote: (i) Stronger cell–cell contacts by up‐regulating the expression of the epithelial markers E‐cadherin and occludin; (ii) down‐regulation of the epithelial transcriptional repressors Zeb, Snail, and Slug accompanied by restoration of cortical F‐actin; and (iii) complete prevention of the CD44pos/CD24neg/low mesenchymal immunophenotype. The impact of EGFR ligands/MAPK phosphatases gene transcripts in predicting CTX efficacy in KRAS WT tumors may be tightly linked with the ability of CTX to concurrently reverse the EMT status, a pivotal property of migrating cancer stem cells. J. Cell. Biochem. 112: 10–29, 2011. © 2010 Wiley‐Liss, Inc.